Explanations for this include the fact that it is possible that the levels of antibody titers may have been suboptimal in the majority of the smokers in the previous clinical trial or that the 12.5% reduction in binding may not be sufficient to lead to improved abstinence rates.

FORBES: Nicotine Vaccine May Help You Quit Smoking